Form 4: Versant Venture Capital VI, L.P. Sells 221,600 Shares of Black Diamond Therapeutics, Inc. (BDTX)

Versant Venture Capital VI, L.P. reports the sale of 221,600 shares of Black Diamond Therapeutics, Inc. at an average price of $6.3202 per share.

Summary

• On August 28, 2024, Versant Venture Capital VI, L.P. sold 221,600 shares of Black Diamond Therapeutics, Inc. (BDTX) common stock.
• The shares were sold at a weighted average price of $6.3202, with individual transaction prices ranging from $6.32 to $6.35.
• Following the transaction, Versant Venture Capital VI, L.P. directly owns 3,726,341 shares.
• Additionally, Versant Voyageurs I, L.P. indirectly owns 1,277,541 shares, Versant Voyageurs I Parallel, L.P. indirectly owns 380,942 shares, and Versant Vantage I, L.P. indirectly owns 822,140 shares.
• The reporting entities have disclaimed beneficial ownership of the indirectly held shares except to the extent of their pecuniary interests.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. The sale itself could be interpreted in various ways, but the document doesn't provide any specific positive or negative signals.

Negatives

• Versant Venture Capital VI, L.P. reduced its direct holdings in Black Diamond Therapeutics, Inc. by selling 221,600 shares.

Industry Context

Form 4 filings are standard disclosures for significant shareholders and insiders, providing transparency into their transactions and holdings in publicly traded companies. This sale could be part of a broader portfolio management strategy by Versant Venture Capital.

Stakeholder Impact

• The sale of shares by a major shareholder like Versant Venture Capital could potentially influence investor sentiment and the stock price of Black Diamond Therapeutics, Inc.

Key Dates